Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

CANNABIS FOR MEDICAL PURPOSES

Canna Policy

The Canadian Medical Association (CMA) has recognized the urgency of regulating cannabis to ensure its safe and responsible use. In December 2010, the CMA released its first policy on cannabis, calling for a comprehensive national strategy to regulate cannabis. The policy was developed in consultation with experts from various fields, including public health, law enforcement, and addiction medicine.

The policy highlights the need for a balanced approach to regulating cannabis. It calls for the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medicinal use of cannabis. This includes the development of robust research to support evidence-based assessments of the efficacy, safety, and effects of cannabis use.

2. Implement regulatory measures that protect the health and safety of individuals, particularly vulnerable populations such as children and pregnant women.

3. Promote public awareness and education about the potential risks and benefits of cannabis use.

The policy also recommends the establishment of a national regulatory framework that balances the need for public health protection with the need for responsible use.

The CMA continues to monitor the implementation of these recommendations and remains committed to advocating for evidence-based policies on cannabis.
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE
Response to consultation

DATE
2017-06-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

The Canadian Medical Association (CMA) is pleased to provide the following comments on Health Canada’s Proposed Regulations for Cannabis: The Bill

The CMA is a voluntary professional organization representing the medical profession in Canada, and urges the government to consider the following comments:

1. **Scope and Intent**

   The proposed regulations in Canada for cannabis are to be linked to 

2. **Human Health**

   In the second important area of human health regulations in Canada, the new law is to take effect in 2018. It is a complex and comprehensive 

3. **Regulatory Structure**

   The proposed regulations in Canada for cannabis are to be linked to 

4. **Conclusion**

   The proposed regulations in Canada for cannabis are to be linked to 

5. **References**


Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

POLICY TYPE  Policy document
DATE  2015-05-30
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada

https://policybase.cma.ca/link/policy10756

POLICY TYPE
Policy document

LAST REVIEWED
2017-03-04

DATE
2013-05-25

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents